Savant Capital LLC Sells 12,721 Shares of Becton, Dickinson and Company $BDX

Savant Capital LLC decreased its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 59.9% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 8,503 shares of the medical instruments supplier’s stock after selling 12,721 shares during the quarter. Savant Capital LLC’s holdings in Becton, Dickinson and Company were worth $1,650,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the business. Vanguard Group Inc. grew its stake in shares of Becton, Dickinson and Company by 13.0% during the fourth quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier’s stock valued at $7,118,282,000 after buying an additional 4,223,149 shares during the last quarter. State Street Corp grew its stake in shares of Becton, Dickinson and Company by 3.4% during the third quarter. State Street Corp now owns 13,872,395 shares of the medical instruments supplier’s stock valued at $2,596,496,000 after buying an additional 459,219 shares during the last quarter. First Eagle Investment Management LLC grew its stake in shares of Becton, Dickinson and Company by 16.5% during the fourth quarter. First Eagle Investment Management LLC now owns 11,646,000 shares of the medical instruments supplier’s stock valued at $2,260,139,000 after buying an additional 1,651,592 shares during the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of Becton, Dickinson and Company by 3.7% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 9,486,694 shares of the medical instruments supplier’s stock valued at $1,841,083,000 after buying an additional 336,110 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Becton, Dickinson and Company by 0.8% during the fourth quarter. Geode Capital Management LLC now owns 6,885,361 shares of the medical instruments supplier’s stock valued at $1,331,165,000 after buying an additional 53,884 shares during the last quarter. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Up 0.0%

Shares of NYSE BDX opened at $147.13 on Monday. The company has a current ratio of 0.94, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $40.54 billion, a PE ratio of 37.25, a price-to-earnings-growth ratio of 10.42 and a beta of 0.22. The stock’s fifty day simple moving average is $151.63 and its two-hundred day simple moving average is $176.99. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.13. The business had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.67 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The business’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter last year, the firm earned $3.35 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. As a group, analysts expect that Becton, Dickinson and Company will post 12.61 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th will be given a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a yield of 2.9%. The ex-dividend date of this dividend is Tuesday, June 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 106.33%.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on BDX. Royal Bank Of Canada set a $175.00 target price on Becton, Dickinson and Company in a research note on Tuesday, April 14th. Citigroup dropped their price objective on Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating on the stock in a research note on Tuesday, February 10th. Jefferies Financial Group dropped their price objective on Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating on the stock in a research note on Tuesday, February 10th. The Goldman Sachs Group dropped their price objective on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 27th. Finally, Piper Sandler dropped their price objective on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating on the stock in a research note on Friday, April 17th. Seven analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Becton, Dickinson and Company currently has a consensus rating of “Hold” and an average price target of $183.64.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.